Teva Beats Corcept Patent Infringement Suit Over Korlym Copy

Teva Pharmaceuticals USA Inc. beat back patent infringement allegations over its copy of Concept Therapeutics Inc.'s Cushing syndrome treatment, Korlym.

Corcept “has not demonstrated that there is a likelihood of direct infringement of the asserted claims in the future because it has not established that physicians are likely to coadminister mifepristone with a strong CYP3A inhibitor at an infringing sequence and/or dosage now or in the future,” Judge Renee Marie Bumb wrote in an opinion released late Friday. “Indeed, Corcept failed to introduce credible record evidence that anyone has ever previously infringed the asserted claims.”

The decision represents a major ...